Mayne Pharma Market Update
Released
Released
Announcement PDF
ASX Announcement
MAYNE PHARMA MARKET UPDATE
24 May 2024, Adelaide, Australia: Mayne Pharma Group Limited (ASX:MYX) reiterates its financial
outlook guidance and provides additional detail relating to the US medical claims and
prescription clearing house, Change Healthcare.
Summary
• No material impact on Mayne Pharma from Change Healthcare cyber-attack
• No change to Mayne Pharma’s outlook, with anticipated growth in revenue and earnings
in 2HFY24 vs 1HFY24
• Continued growth in Women’s health
• Dermatology maintaining margin profile
Change Healthcare Incident
Mayne Pharma notes the February 2024 cyber-attack on Change Healthcare, the largest US
clearing house for medical claims, had broad impacts across the US healthcare industry,
impairing the ability of prescriptions at certain pharmacies to be fulfilled to customers. The
outage resulted in the temporary non-fulfilment of certain prescriptions including for Mayne
Pharma products. Normal fulfilment operations affecting Mayne Pharma products were resumed
by Change Healthcare in April 2024. Lingering effects of this cyber-attack still exist in many other
sectors of the US healthcare industry.
Mayne Pharma confirms this incident did not have a material impact on its business. The
Company has seen a return to unit growth following the resolution of the Change Healthcare
cyber-attack.
No Change to Outlook Provided at 1H FY24 Result
The Company reiterates its outlook provided to the market at the time of its first half result on
26 February 2024 and again on 13 May 2024 at the Citizens JMP Healthcare Conference in New
York, that the Company expects:
•
•
•
growing both revenue and earnings 2HFY24 vs 1HFY24;
continued revenue growth with improving cost leverage and discipline; and
returning the Company to positive cash flow generation 2HFY24 (with respect to
continuing operations).
Mayne Pharma continues to hold significant cash reserves and maintains its objective of
generating positive operating cash flow in the current half from continuing operations.
Women's Health
Mayne Pharma is seeing continued growth in Women’s Health. The Company has progressed with
operational changes and its ongoing evaluation of ROI on marketing spend, focusing on
continued growth driven primarily by NEXTSTELLIS®, ANNOVERA® and BIJUVA®.
ASX Announcement
In Women’s Health, Mayne Pharma has historically reported product sales volumes combining
data from reporting pharmacies (sourced from leading data and analytics provider, IQVIA) and
from non-reporting pharmacies and its own channels (not captured by IQVIA).
In the Citizens JMP Healthcare Conference presentation materials, slide 11 provided prescription
unit demand data for NEXTSTELLIS® sourced only from IQVIA. This prescription unit demand data
did not reflect the total prescription demand of the NEXTSTELLIS® product, as no adjustments
were made for non-reporting pharmacies or our own channels of distribution. We used the raw
IQVIA unit demand data only to show the impact to NEXTSTELLIS® of the cyber-attack in a timely
basis.
In the future, Mayne Pharma will continue to provide prescription demand data from IQVIA.
Internally sourced prescription demand data from non-reporting pharmacies and Mayne
Pharma’s own channels of distribution will be provided where reliable data can be collated and
as appropriate. Product revenue reported by Mayne Pharma is recognised in accordance with
Mayne Pharma’s accounting policies, which is on the basis of actual units sold.
Dermatology
Mayne Pharma is maintaining the margin profile of its Dermatology products via a strategic shift
to grow sales volumes from its branded products and through continuous pricing management.
Additional new product launches in 2HFY24 are expected to further build out the Company’s
portfolio and support continued revenue growth.
Mayne Pharma’s unique prescriber patient fulfilment process is currently transitioning from pilot
phase to a scaled operation. The Company expects to maintain its market shares of RHOFADE®,
DORYX® MPC60 and authorised generic ORACEA®.
On market buy-back
Mayne Pharma confirms it has today lodged an ASX Appendix 3F relating to the expiration of the
original up to 10% on-market share buy-back program which commenced on 25 May 2023 and
expired on 24 May 2024. Mayne Pharma has also lodged the required ASX Appendix 3C relating to
the up to 15% on-market share buy-back program approved by Mayne Pharma shareholders at
its AGM on 30 November 2023. This program will expire on 29 November 2024 unless otherwise
notified.
The size and timing of any continuing buy-backs will be (and has been) determined by the Board
and is dependent on a number of matters, including prevailing conditions and relevant
obligations under the ASX Listing Rules and the Corporations Act.
Jefferies Healthcare conference
Mayne Pharma CEO and Managing Director, Shawn Patrick O’Brien will be presenting at Jefferies
Healthcare conference on 6 June 2024 in New York City.
Page 2
ASX Announcement
For further information contact:
Australia:
Craig Haskins
+61 421 029 843
ir@maynepharma.com
USA:
Lisa M. Wilson
+1 917-543-9932
ir@maynepharma.com
Authorised for release to the ASX by the Chair
DORYX® and RHOFADE® are trademarks of Mayne Pharma. ANNOVERA ®, BIJUVA®, NEXTSTELLIS®
and ORACEA® are trademarks of third parties.
About Mayne Pharma
Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising novel
pharmaceuticals, offering patients better, safe and more accessible medicines. Mayne Pharma also
provides contract development and manufacturing services to clients worldwide. Mayne Pharma has a 40year track record of innovation and success in developing new oral drug delivery systems. These
technologies have been successfully commercialised in numerous products that continue to be marketed
around the world. To learn more about Mayne Pharma, please visit maynepharma.com.
Page 3
Share your feedback
Discover